JOP20230013A1 - توليفة من مثبط bcl-2 وعامل خفض المثيلة لعلاج السرطانات، واستخداماتها وتركيبات صيدلية منها - Google Patents

توليفة من مثبط bcl-2 وعامل خفض المثيلة لعلاج السرطانات، واستخداماتها وتركيبات صيدلية منها

Info

Publication number
JOP20230013A1
JOP20230013A1 JOJO/P/2023/0013A JOP20230013A JOP20230013A1 JO P20230013 A1 JOP20230013 A1 JO P20230013A1 JO P20230013 A JOP20230013 A JO P20230013A JO P20230013 A1 JOP20230013 A1 JO P20230013A1
Authority
JO
Jordan
Prior art keywords
bcl
inhibitor
combination
pharmaceutical compositions
treating cancers
Prior art date
Application number
JOJO/P/2023/0013A
Other languages
Arabic (ar)
English (en)
Inventor
Emmelyne Dessein
Lisa Mahnke
Robert Cooper Michael
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of JOP20230013A1 publication Critical patent/JOP20230013A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JOJO/P/2023/0013A 2020-07-31 2023-01-18 توليفة من مثبط bcl-2 وعامل خفض المثيلة لعلاج السرطانات، واستخداماتها وتركيبات صيدلية منها JOP20230013A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059419P 2020-07-31 2020-07-31
EP20195633 2020-09-11
PCT/EP2021/071368 WO2022023514A1 (en) 2020-07-31 2021-07-30 Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
JOP20230013A1 true JOP20230013A1 (ar) 2023-01-18

Family

ID=77595496

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0013A JOP20230013A1 (ar) 2020-07-31 2023-01-18 توليفة من مثبط bcl-2 وعامل خفض المثيلة لعلاج السرطانات، واستخداماتها وتركيبات صيدلية منها

Country Status (15)

Country Link
US (1) US20230270748A1 (enExample)
EP (1) EP4188387A1 (enExample)
JP (1) JP2023537290A (enExample)
KR (1) KR20230044452A (enExample)
CN (1) CN116390735A (enExample)
AU (1) AU2021316674A1 (enExample)
BR (1) BR112023001307A2 (enExample)
CA (1) CA3190276A1 (enExample)
CL (1) CL2023000242A1 (enExample)
CR (1) CR20230046A (enExample)
IL (1) IL300145A (enExample)
JO (1) JOP20230013A1 (enExample)
MX (1) MX2023001335A (enExample)
PH (1) PH12023550205A1 (enExample)
WO (1) WO2022023514A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252168A1 (zh) * 2024-06-06 2025-12-11 苏州亚盛药业有限公司 一种含有Bcl-2/Bcl-xL抑制剂的药物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018015526A1 (en) * 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
UY38431A (es) 2018-10-31 2020-05-29 Servier Lab Formulación basada en ciclodextrina de un inhibidor de bcl-2
GEP20237494B (en) 2018-10-31 2023-04-10 Servier Lab Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
CL2023000242A1 (es) 2023-11-10
MX2023001335A (es) 2023-04-27
CN116390735A (zh) 2023-07-04
JP2023537290A (ja) 2023-08-31
CA3190276A1 (en) 2022-02-03
BR112023001307A2 (pt) 2023-02-14
US20230270748A1 (en) 2023-08-31
PH12023550205A1 (en) 2024-06-24
AU2021316674A1 (en) 2023-03-02
EP4188387A1 (en) 2023-06-07
KR20230044452A (ko) 2023-04-04
IL300145A (en) 2023-03-01
CR20230046A (es) 2023-04-11
WO2022023514A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
Miller et al. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors
AR129238A1 (es) Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras
GEAP202416530A (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
AR071003A1 (es) Farmaco contra cancer de higado
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
MX359413B (es) Metodos de tratamiento de carcinoma hepatocelular.
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
MX2020000265A (es) Composiciones para la administración parenteral de agentes terapéuticos.
EP4238964A4 (en) COMPOUND, ALDEHYDE DEHYDROGENASE 2 ACTIVATOR, PHARMACEUTICAL COMPOSITION, AND TREATMENT AND/OR PREVENTION MEDICATION
CR20230308A (es) Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
NI202100031A (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
CO2023017275A2 (es) Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno
BR112022018594A2 (pt) Agrupamentos de ouro (aucs), e composição para tratamento de cirrose hepática
BR112023001307A2 (pt) Combinação de inibidor de bcl-2 e agente hipometilante para tratamento de câncer, usos e composições farmacêuticas dos mesmos
MX393811B (es) Combinacion de un inhibidor de mcl-1 y un tratamiento de atencion estandar para cancer hematologico, usos y composiciones farmaceuticas de esta
GEP20227372B (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
MX2024007908A (es) Tratamiento terapeutico para trastorno asociado con x fragil.
BRPI0518584A2 (pt) combinaÇço, composiÇço farmacÊutica, mÉtodo de tratar cÂncer, e, kit
PH12021550815A1 (en) New combination solution for treating chemotherapy refractory cancer